Aytu BioPharma (NASDAQ:AYTU) Shares Cross Below 50-Day Moving Average – Time to Sell?

Aytu BioPharma Inc. (NASDAQ:AYTU)’s stock price passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.18 and traded as low as $1.91. Aytu BioPharma shares last traded at $2.01, with a volume of 72,004 shares traded.

Analyst Upgrades and Downgrades

Several analysts have weighed in on AYTU shares. Maxim Group lowered their price target on shares of Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, September 25th. Wall Street Zen lowered Aytu BioPharma from a “buy” rating to a “hold” rating in a research note on Friday, September 26th. Ascendiant Capital Markets raised their price target on Aytu BioPharma from $12.00 to $12.50 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Tuesday, October 14th. Finally, Zacks Research lowered Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research note on Friday, October 10th. Three investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $9.17.

Aytu BioPharma Stock Performance

The business has a fifty day moving average of $2.18 and a 200-day moving average of $2.15. The company has a market cap of $20.48 million, a PE ratio of -0.66 and a beta of 0.25. The company has a current ratio of 1.23, a quick ratio of 1.08 and a debt-to-equity ratio of 0.45.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Aytu BioPharma had a positive return on equity of 17.86% and a negative net margin of 20.52%.The business had revenue of $13.89 million during the quarter, compared to analysts’ expectations of $17.92 million.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP purchased a new stake in shares of Aytu BioPharma in the 3rd quarter worth about $58,000. Two Sigma Investments LP lifted its holdings in Aytu BioPharma by 96.2% in the third quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after buying an additional 33,701 shares during the period. FNY Investment Advisers LLC bought a new stake in Aytu BioPharma during the 2nd quarter valued at approximately $78,000. Stonepine Capital Management LLC grew its holdings in shares of Aytu BioPharma by 13.8% during the 1st quarter. Stonepine Capital Management LLC now owns 463,721 shares of the company’s stock worth $556,000 after acquiring an additional 56,172 shares during the period. Finally, Persistent Asset Partners Ltd bought a new position in shares of Aytu BioPharma in the 3rd quarter worth approximately $117,000. 33.49% of the stock is owned by hedge funds and other institutional investors.

About Aytu BioPharma

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.